Hybrid nanoparticle-based nicotine nanovaccines: Boosting the immunological efficacy by conjugation of potent carrier proteins

Zhao, Zongmin; Hu, Yun; Harmon, Theresa; Pentel, Paul R.; Ehrich, Marion; Zhang, Chenming

doi:10.1016/j.nano.2018.04.016

Cited by 14 publications

(10 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The T cell activation upon incubation of RNase-A or RNase-S with splenocytes harvested from RNase-S vaccinated mice was near zero, however, which seems to indicate that RNase-S failed to reach APCs upon in vivo administration (182). When considering MHC class II pathway, increased antigen complexity has been shown to slow in vitro DC processing and decrease in vivo antibody response (183). For example, So et al observed that the stability of two recombinantly modified hen-egg lysozyme proteins (one with a deleted di-sulfide bond and the other with a selectively added intramolecular ester bond) was inversely correlated with CD4+ T cell activation and both cytokine and antibody production in a mouse model (184).…”

Section: The Impact Of Pbv Stability On Apc Processing and T Cell Actmentioning

confidence: 99%

Designs of Antigen Structure and Composition for Improved Protein-Based Vaccine Efficacy

et al. 2020

Self Cite

View full text Add to dashboard Cite

Today, vaccinologists have come to understand that the hallmark of any protective immune response is the antigen. However, it is not the whole antigen that dictates the immune response, but rather the various parts comprising the whole that are capable of influencing immunogenicity. Protein-based antigens hold particular importance within this structural approach to understanding immunity because, though different molecules can serve as antigens, only proteins are capable of inducing both cellular and humoral immunity. This fact, coupled with the versatility and customizability of proteins when considering vaccine design applications, makes protein-based vaccines (PBVs) one of today's most promising technologies for artificially inducing immunity. In this review, we follow the development of PBV technologies through time and discuss the antigen-specific receptors that are most critical to any immune response: pattern recognition receptors, B cell receptors, and T cell receptors. Knowledge of these receptors and their ligands has become exceptionally valuable in the field of vaccinology, where today it is possible to make drastic modifications to PBV structure, from primary to quaternary, in order to promote recognition of target epitopes, potentiate vaccine immunogenicity, and prevent antigen-associated complications. Additionally, these modifications have made it possible to control immune responses by modulating stability and targeting PBV to key immune cells. Consequently, careful consideration should be given to protein structure when designing PBVs in the future in order to potentiate PBV efficacy.

show abstract

Section: The Impact Of Pbv Stability On Apc Processing and T Cell Actmentioning

confidence: 99%

Designs of Antigen Structure and Composition for Improved Protein-Based Vaccine Efficacy

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Using these targeting molecules as well as incorporating the nicotine haptens into the core and shell to create a 100 nm particle leads to approximately 60% less nicotine entering the brain than non-nano-mediated vaccines. However, it is unknown if this decrease is sufficient to reduce addictive potential/hedonic value [145][146][147].…”

Section: Nanomedicine For Addiction and Drug Abuse-mentioning

confidence: 99%

Leveraging the interplay of nanotechnology and neuroscience: Designing new avenues for treating central nervous system disorders

Smith

Porterfield

Kannan

2019

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

Nanotechnology has the potential to open many novel diagnostic and treatment avenues for disorders of the central nervous system (CNS). In this review, we discuss recent developments in the applications of nanotechnology in CNS therapies, diagnosis and biology. Novel approaches for the diagnosis and treatment of neuroinflammation, brain dysfunction, psychiatric conditions, brain cancer, and nerve injury provide insights into the potential of nanomedicine. We also highlight nanotechnology-enabled neuroscience techniques such as electrophysiology and intracellular sampling to improve our understanding of the brain and its components. With nanotechnology integrally involved in the advancement of basic neuroscience and the development of novel treatments, combined diagnostic and therapeutic applications have begun to emerge. Nanotheranostics for the brain, able to achieve single-cell resolution, will hasten the rate in which we can diagnose, monitor, and treat diseases. Taken together, the recent advances highlighted in this review demonstrate the prospect for significant improvements to clinical diagnosis and treatment of a vast array of neurological diseases. However, it is apparent that a strong dialogue between the nanoscience and neuroscience communities will be critical for the development of successful nanotherapeutics that move to the clinic, benefit patients, and address unmet needs in CNS disorders.

show abstract

“…MHC class II epitopes were chosen for analysis due to their role as facilitators of humoral immune responses via the activation of T H cells. This activation is crucial to antibody production and as such plays an important role in the success of vaccines that are dependent on antibody effector functions, such as vaccines against drugs of abuse [ 29 , 30 ]. Using the output from these predictions, ‘universal’ chimeric antigens (UCAs) were designed that can be used to target mouse models with IAd and/or IEd isotype, and using HLA-DQB1 and HLA-DRB1 allele frequency data, 99% of the US population based on HLA-DQ and HLA-DR isotypes.…”

Section: Introductionmentioning

confidence: 99%

Computational mining of MHC class II epitopes for the development of universal immunogenic proteins

2022

Self Cite

View full text Add to dashboard Cite

The human leukocyte antigen (HLA) gene complex, one of the most diverse gene complexes found in the human genome, largely dictates how our immune systems recognize pathogens. Specifically, HLA genetic variability has been linked to vaccine effectiveness in humans and it has likely played some role in the shortcomings of the numerous human vaccines that have failed clinical trials. This variability is largely impossible to evaluate in animal models, however, as their immune systems generally 1) lack the diversity of the HLA complex and/or 2) express major histocompatibility complex (MHC) receptors that differ in specificity when compared to human MHC. In order to effectively engage the majority of human MHC receptors during vaccine design, here, we describe the use of HLA population frequency data from the USA and MHC epitope prediction software to facilitate the in silico mining of universal helper T cell epitopes and the subsequent design of a universal human immunogen using these predictions. This research highlights a novel approach to using in silico prediction software and data processing to direct vaccine development efforts.

show abstract

Hybrid nanoparticle-based nicotine nanovaccines: Boosting the immunological efficacy by conjugation of potent carrier proteins

Cited by 14 publications

References 47 publications

Designs of Antigen Structure and Composition for Improved Protein-Based Vaccine Efficacy

Designs of Antigen Structure and Composition for Improved Protein-Based Vaccine Efficacy

Leveraging the interplay of nanotechnology and neuroscience: Designing new avenues for treating central nervous system disorders

Computational mining of MHC class II epitopes for the development of universal immunogenic proteins

Contact Info

Product

Resources

About